EPIC Trial (Boswood 2016): Pimobendan in Preclinical Stage B2 MMVD — Design, Results, and Clinical Implications

Bottom line

• The EPIC study (Boswood et al. 2016, J Vet Intern Med) is the pivotal multicenter RCT establishing pimobendan's benefit in asymptomatic Stage B2 MMVD: 360 dogs at qualifying echocardiographic and radiographic cardiomegaly thresholds were randomized to pimobendan or placebo.¹
• Pimobendan delayed the composite primary endpoint (onset of CHF, cardiac-related death, or euthanasia) from a median of 766 days to 1228 days — a hazard ratio of 0.64 (95% CI 0.47–0.87, P = .0038) — representing approximately 15 months of additional preclinical time, with overall survival also significantly prolonged (P = .012).¹
• Adverse events were not significantly different between treatment and placebo groups, establishing an acceptable safety profile in this population.¹
• The EPIC cardiomegaly criteria (LA/Ao ≥1.6, normalized LVIDdN ≥1.7, and VHS >10.5) are now incorporated into the ACVIM 2019 consensus definition of Stage B2 to identify dogs in whom pimobendan initiation is indicated.²
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

A specific patient on pimobendan in Stage B2 MMVD?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Study design and population

The EPIC study was a prospective, randomized, placebo-controlled, blinded, multicenter clinical trial conducted at 36 centers across Europe, North America, Australasia, and Japan.¹ Dogs were eligible if they had a murmur consistent with MMVD, were not receiving other cardiovascular medications, and met all three echocardiographic and radiographic cardiomegaly criteria: left atrial-to-aortic ratio (LA/Ao) ≥1.6, normalized left ventricular internal diameter in diastole (LVIDdN) ≥1.7, and vertebral heart sum (VHS) >10.5.¹ These thresholds were selected to identify a hemodynamically significant subgroup of preclinical MMVD patients most likely to benefit from intervention. Three hundred and sixty client-owned dogs were enrolled.

The primary outcome variable was time to a composite of the onset of CHF, cardiac-related death, or euthanasia for cardiac reasons.¹

Primary and secondary results

Median time to the primary endpoint was 1228 days (95% CI: 856–not reached) in the pimobendan group and 766 days (95% CI: 667–875) in the placebo group (P = .0038). The hazard ratio for pimobendan was 0.64 (95% CI: 0.47–0.87), indicating a 36% reduction in the hazard of reaching the composite endpoint.¹ The benefit persisted after adjustment for other baseline variables. Dogs in the pimobendan group also lived significantly longer: median survival time was 1059 days (95% CI: 952–not reached) in the pimobendan group versus 902 days (95% CI: 747–1061) in the placebo group (P = .012).¹ Adverse events were not different between treatment groups.

The authors concluded: "Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated. Prolongation of preclinical period by approximately 15 months represents substantial clinical benefit."¹

Integration into ACVIM staging

The 2019 ACVIM consensus guidelines explicitly incorporated the EPIC eligibility criteria into the clinical definition of Stage B2 MMVD for which pimobendan initiation is recommended.² Dogs with a heart murmur consistent with MMVD who do not meet these cardiomegaly thresholds remain at Stage B1, for which no pharmacologic intervention is currently recommended based on available evidence. This echocardiographic gating is clinically important: not every dog with a murmur qualifies for pimobendan at the preclinical stage, and inappropriate treatment of Stage B1 dogs adds drug exposure without demonstrated benefit.

How this fits clinical practice

The EPIC trial fundamentally changed the management of preclinical MMVD by demonstrating that intervention before CHF onset prolongs both the preclinical period and overall survival. The echocardiographic qualifying criteria embedded in the trial — and now in ACVIM guidelines — mean that cardiac ultrasound is essential before initiating pimobendan in asymptomatic dogs. A murmur alone, without documented cardiomegaly meeting the LA/Ao, LVIDdN, and VHS thresholds, does not constitute an EPIC-equivalent Stage B2 indication. For the broader mechanism, staging framework, and DCM data, see the linked evergreen article on pimobendan for canine MMVD. Do not infer specific doses from this summary; confirm the exact regimen against current product labeling and a veterinary formulary.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Boswood A, Häggström J, Gordon SG, et al. 2016. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC study — a randomized clinical trial. J Vet Intern Med 30(6):1765-1779. https://europepmc.org/article/MED/27678080
2. Keene BW, Atkins CE, Bonagura JD, et al. 2019. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med 33(3):1127-1140. https://europepmc.org/article/MED/30974015 [via]

Changelog

• 2026-06-22: First published.